Figure 1. Hyperadditive interactions of PARP inhibitors and cisplatin in NSCLC A549 cells. (A and B) Human non-small cell lung carcinoma (NSCLC) A549 cells were cultured in control conditions or exposed for 48 h to PJ34 hydrochloride hydrate (PJ), CEP 8983 (CEP) or cisplatin (CDDP), alone or in the indicated combinations, followed by the colorimetric assessment of residual proliferation by means of a WST-1 conversion-based assay. In panel (A), color-coded surfaces illustrate residual WST-1-converting activity. In panel (B), combination indexes (CIs), estimated according to the Harbron’s method starting from a data set built on n = 3 independent assessments, are depicted. CI < 0.8 is generally viewed as an indicator of bona fide synergistic interactions. See also Tables S1 and S2.